GNRH1 and Familial prostate cancer: As shown by the SPCG-7 trial, the cumulative incidence for prostate cancer-specific mortality at 10 years was 23.9 % for the group treated with ADT alone (3.75 or 11.25 mg GnRH agonist leuprorelin plus 250 mg AR antagonist flutamide for 3 months) and 11.9 % in the group treated with ADT in combination with radiotherapy [35].